The current “target-rich and lead-poor” scenario in drug discovery, together with the massive financial resources required to develop a new drug, mean that new approaches and renewed efforts by researchers in academia are required, in particular in the area of neglected and rare diseases. Virtual screening and volunteer computing are extremely useful tools in this fight, and together have the potential to play a crucial role in the early stages of drug development. From a social and economic point of view, amyloid neurodegenerative diseases, including Alzheimer´s, Parkinson´s, familial amyloid polyneuropathy and several others, currently represent important targets for drug discovery. Here, we provide a short account of our current efforts to develop new compounds with anti-amyloid potential using a volunteer computing network.